Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Quest Diagnostics Incorporated (NYSE:DGX) stock soared to a 52-week high, reaching a price level of $171.42. According to InvestingPro data, the company maintains a "GOOD" overall financial health score, demonstrating strong operational stability. The prominent provider of diagnostic information services has witnessed a remarkable year, with the stock price reflecting a significant 1-year change of 38.05%. The company has maintained dividend payments for 22 consecutive years, with a current yield of 1.89%. This surge underscores the company’s robust performance amidst a challenging healthcare landscape, as investors show increasing confidence in Quest Diagnostics’ growth trajectory and strategic initiatives. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading above its intrinsic value. The achievement of this 52-week high marks a notable milestone for the company and its shareholders, signaling strong market momentum and potential for continued success. With 8+ additional exclusive insights available on InvestingPro, including detailed valuation metrics and growth forecasts, investors can access comprehensive analysis to make informed decisions about DGX’s future prospects.
In other recent news, Quest Diagnostics reported impressive fourth-quarter 2024 earnings, exceeding expectations with an adjusted earnings per share (EPS) of $2.23, surpassing the forecast of $2.19. The company’s revenue for the quarter also outperformed projections, reaching $2.62 billion against the anticipated $2.58 billion, marking a 14.5% year-over-year increase. This robust performance was driven by strong growth in advanced diagnostics and preventative health services. Additionally, Quest Diagnostics saw a 4.8% organic revenue rise and a 13.9% increase in reported volumes. Despite these positive results, the 2025 adjusted EPS guidance was slightly below expectations due to factors like higher interest expenses. JPMorgan responded by raising Quest Diagnostics’ price target to $180 while maintaining a Neutral stock rating, reflecting expectations of continued volume strength. The firm’s revenue forecast for 2025 has been adjusted upwards to $10.776 billion, with a stable growth outlook anticipated for 2026. Quest Diagnostics continues to focus on investments in IT and automation to support its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.